Yushita Tablet 25 mg (Sitagliptin Hydrochloride Monohydrate)
Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
YouYoung Pharmaceutical Co., Ltd.
MFDS item code 202101747 · Approved 2021.02.22
This product's status changed to Expired on 2026.02.22. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This drug is used in conjunction with diet and exercise to help control blood sugar in patients with type 2 diabetes. It can be administered alone or in combination with metformin if prior drug treatment has not controlled blood sugar adequately. It is also used in combination when blood sugar control is insufficient with monotherapy using sulfonylureas, metformin, thiazolidinediones, or insulin. Additionally, it can be administered to enhance effectiveness when blood sugar control is difficult even during combination therapy with sulfonylureas and metformin, thiazolidinediones and metformin, or insulin and metformin. By using it systematically, blood sugar control is improved.
Administer 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medication may be taken regardless of meals. When administered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because the dose must be adjusted according to renal function, assessment of renal function is recommended before and periodically after starting this medication. 1. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily in patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medication may be administered regardless of the timing of dialysis.
This drug is used for the treatment of diabetes. Rarely, serious allergic reactions may occur; if symptoms such as skin rash or difficulty in breathing appear, you must immediately stop taking the drug and consult a physician. Additionally, this drug may cause pancreatitis, so if symptoms such as abdominal pain, vomiting, or loss of appetite occur, please inform medical personnel immediately. It should not be used in patients with type 1 diabetes, diabetic ketoacidosis, or hypersensitivity to this drug or its components. Patients with impaired kidney function may have increased drug concentrations, so dosage adjustment is necessary; regular kidney function tests are recommended. Hypoglycemic symptoms may occur during the use of this drug, so particularly when taking it with insulin or sulfonylureas, blood sugar should be regularly checked and precautions for hypoglycemia are necessary. Rarely, side effects such as arthralgia or skin blisters may occur, so if severe joint pain or skin abnormalities are present, notify a doctor immediately. It is not recommended for pregnant or breastfeeding women, or children under 18 as its safety has not been established. In case of overdose, general emergency treatment should be received, and if necessary, some drugs may be removed by dialysis. This drug has relatively few drug interactions, but caution is needed when taking certain medications, so inform your doctor if you are taking other medications. Elderly patients may have decreased kidney function, so dosage adjustment and kidney function tests are necessary. Regular checks on health status should be conducted during the use of this drug, and if unusual symptoms appear, consult medical personnel immediately.
Not everyone experiences these, and they can vary from person to person.
This drug should be stored in a tightly sealed container to prevent air from entering, with the storage temperature maintained between 1 to 30 degrees Celsius at room temperature. By storing it this way, the drug's effectiveness can be well preserved, and deterioration can be prevented.
Pink, round, biconvex film-coated tablets
28 tablets/box [14 tablets/PTP X 2]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
YouYoung Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.